Abstract
In 2004 total world revenues for branded antidepressant drugs was worth over $13bn, but with only ten drugs on the market. However, nine out of these ten drugs faces a loss of patent in the period 2006-2010.
Dr Tom Newton, pharmaceutical analyst with visiongain and author of The World Market for Antidepressants, 2006, predicts that the world market will crash producing revenues in 2010 of only $7bn. This is a loss of almost 50% of total revenues. The world antidepressants market is in serious trouble.
Also the pipeline is lackluster with no drugs likely to be launched that will halt this massive revenue loss. Even the recent launch of Cymbalta from Eli Lilly will not save this market. However, the antidepression market is not the only market to face high patent loss and a very strong generic threat.
The World Market for Antidepressants, 2006 from visiongain thoroughly analyses this market and includes an indepth view of the generic threat with US based generic revenues as an indicator of the way the rest of the world market is headed.
This report assess the new pipeline drugs and identifies the potential blockbuster. Also, an examination of the global market by country indicates distortions in the market and possible new areas of expansion. Overall visiongains The World Market for Antidepressants, 2006 will discuss the most important aspects of this declining market and possible ways of reducing revenue loss.
View Cart
